Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition
Marine Drugs · 2024
DOI: 10.3390/md22040143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Marine Drugs, 2024. Verfasst von Maria Rita Garcia und 3 weiteren Autor:innen. Beteiligte Einrichtung: REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal. Hauptthemen laut MEDLINE: Antineoplastic Agents, Aquatic Organisms, Biological Products, Hypoxia-Inducible Factor 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 337 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, PT national funds.
Abstract (Originalsprache)
The inadequate vascularization seen in fast-growing solid tumors gives rise to hypoxic areas, fostering specific changes in gene expression that bolster tumor cell survival and metastasis, ultimately leading to unfavorable clinical prognoses across different cancer types. Hypoxia-inducible factors (HIF-1 and HIF-2) emerge as druggable pivotal players orchestrating tumor metastasis and angiogenesis, thus positioning them as prime targets for cancer treatment. A range of HIF inhibitors, notably natural compounds originating from marine organisms, exhibit encouraging anticancer properties, underscoring their significance as promising therapeutic options. Bioprospection of the marine environment is now a well-settled approach to the discovery and development of anticancer agents that might have their medicinal chemistry developed into clinical candidates. However, despite the massive increase in the number of marine natural products classified as ‘anticancer leads,’ most of which correspond to general cytotoxic agents, and only a few have been characterized regarding their molecular targets and mechanisms of action. The current review presents a critical analysis of inhibitors of HIF-1 and HIF-2 and hypoxia-selective compounds that have been sourced from marine organisms and that might act as new chemotherapeutic candidates or serve as templates for the development of structurally similar derivatives with improved anticancer efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.
- 1H-TOXRUN-Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal.
- UCIBIO/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
- Department of Neurosurgery, Hôpital Universitaire de Bruxelles (H.U.B), CUB Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
ORCID-Profile: Maria Rita Garcia, Paula B Andrade, Nelson G M Gomes
Förderung
- Fundação para a Ciência e Tecnologia
- PT national funds
Zitieren
APA
Garcia, M. R., Andrade, P. B., Lefranc, F., & Gomes, N. G. M. (2024). Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition. Marine Drugs. https://doi.org/10.3390/md22040143
Vancouver
Garcia MR, Andrade PB, Lefranc F, Gomes NGM. Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition. Marine Drugs. 2024. doi:10.3390/md22040143
BibTeX
@article{Garcia2024,
author = {Garcia, Maria Rita and Andrade, Paula B and Lefranc, Florence and Gomes, Nelson G M},
title = {Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22040143}
}
EUVIMED